TAMPA, Fla., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that it has filed a lawsuit in the United States District Court for the District of New Jersey against eVenus Pharmaceutical Laboratories, Inc. for patent infringement of U.S. Patent Number 11,033,495. The ’495 patent is related to EXPAREL® (bupivacaine liposome injectable suspension) and has an expiration date of January 22, 2041. The complaint is seeking an injunction to prevent the infringing manufacture, use, and sale of a potential generic product described in an Abbreviated New Drug Application (ANDA) that eVenus filed with the U.S. Food and Drug Administration in August 2021. The filing of the lawsuit triggered a 30-month stay of final approval of eVenus’ ANDA under the Hatch Waxman Act.
Pacira Files Lawsuit Against eVenus for Patent Infringement
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
